Novartis (NVS) Scheduled to Post Earnings on Tuesday

Novartis (NYSE:NVS - Get Free Report) is set to release its earnings data before the market opens on Tuesday, April 23rd. Analysts expect Novartis to post earnings of $1.73 per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $11.42 billion for the quarter, compared to analyst estimates of $11.69 billion. Novartis had a net margin of 29.83% and a return on equity of 29.90%. During the same period in the previous year, the firm posted $1.51 earnings per share. On average, analysts expect Novartis to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Up 0.8 %

NYSE:NVS traded up $0.75 during trading hours on Monday, hitting $95.11. 2,447,717 shares of the company's stock traded hands, compared to its average volume of 1,510,492. The firm has a market cap of $194.40 billion, a P/E ratio of 13.25, a P/E/G ratio of 1.47 and a beta of 0.54. Novartis has a twelve month low of $92.19 and a twelve month high of $108.78. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.93 and a current ratio of 1.15. The stock's fifty day moving average price is $97.98 and its two-hundred day moving average price is $98.99.

Novartis Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were given a $3.7772 dividend. This is a positive change from Novartis's previous annual dividend of $3.47. This represents a yield of 3.1%. The ex-dividend date was Thursday, March 7th. Novartis's dividend payout ratio is presently 33.84%.

Analyst Upgrades and Downgrades

NVS has been the topic of several research reports. Morgan Stanley initiated coverage on Novartis in a research report on Tuesday, January 23rd. They issued an "equal weight" rating and a $114.00 target price on the stock. BMO Capital Markets initiated coverage on Novartis in a research report on Friday, February 23rd. They issued a "market perform" rating and a $114.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $114.00.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.